[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587637":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":23,"locations":28,"responsibleParty":41,"collaborators":18,"id":44,"slug":18,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":18,"enrollmentInfo":53,"targetDuration":18,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":18,"overallStatus":30,"whyStopped":18,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Vanderbilt University Medical Center","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"13C6-Glucose","10-25gm of 13C6-Glucose",[12],"Drug: 13C6-Glucose",[14],{"type":15,"name":9,"description":16,"armGroupLabels":17,"otherNames":18},"DRUG","Compounded as 5% 13C6-Glucose in sterile water given IV over 2-4 hours as a split bolus and infusion",[9],null,[20],{"name":21,"affiliation":5,"role":22},"Matthew T Stier, M.D., Ph.D.","PRINCIPAL_INVESTIGATOR",[24],{"name":21,"role":25,"phone":26,"phoneExt":18,"email":27},"CONTACT","615-875-4978","matthew.stier@vumc.org",[29],{"facility":5,"status":30,"city":31,"state":32,"zip":33,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":18},"RECRUITING","Nashville","Tennessee","37212","United States",{"type":36,"coordinates":37},"Point",[38,39],-86.78444,36.16589,{"lat":39,"lon":38},{"type":22,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Matthew Stier","Assistant Professor of Medicine","100587637",false,"NCT06930976","Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells","TORCH","Inclusion Criteria:\n\n* Adults aged 18 or older\n\nExclusion Criteria:\n\n* Pregnant\n* Prisoner or in police custody\n* Uncontrolled hyperglycemia\u002Fdiabetes\n* Current participation in another study where the total volume of blood drawn, when added to this study blood draw volume, exceeds 500cc in an 8 week period\n* Any medical issue or pharmacologic exposure which, in the opinion of the study investigator, that might interfere with the study objectives\n* Any reason which, in the opinion of the study investigator, adds additional risk to the participant",true,"ALL","18 Years",{"count":54,"type":55},12,"ESTIMATED","INTERVENTIONAL",[58],"NA","The purpose of this study is to understand how cells of the immune system use the common sugar glucose to fuel energy production and as a building block within the cell. Investigators will intravenously infuse a non-radioactive glucose tracer into participants over a few hours and collect immune cells from the blood to track uptake and usage of this glucose within these immune cells.",[61,62,63,64],"Glucose","Metabolism","Isotope Labeling","Immune System and Related Disorders","2025-11-01",{"date":67,"type":68},"2025-11-04","ACTUAL",{"date":70,"type":68},"2025-10-01",{"date":72,"type":55},"2027-06-30",{"name":5,"class":6},1]